Subtype
High Grade Astrocytic Tumor
CI-CAN-00005503Explore in graph →
495 active trials2 approved drugs51 evidence items
- NCIt
- C102897
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005503Explore in graph →
Clinical trials
1,778 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (282)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01540513 | PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404 | completed | N/A | 12 | University of Wisconsin, MadisonOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT02893137 | Enhancing Optune Therapy With Targeted Craniectomy | completed | Phase 1 | 15 | Aarhus University HospitalOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT03843814 |
| Pilot Study Using Amide Proton Transfer Magnetic Resonance Imaging Distinguishing Glioma |
| terminated |
| N/A |
| 13 |
| Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER |
| 1 |
| Nov 26, 2019 |
| clinicaltrials |
| NCT00984438 | Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme | withdrawn | Phase 1 / Phase 2 | 0 | University of CincinnatiOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT01392209 | Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma | completed | Phase 1 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 22, 2019 | clinicaltrials |
| NCT01516905 | PET/CT Imaging of Malignant Brain Tumors With 124I-NM404 | completed | — | 19 | University of Wisconsin, MadisonOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT03722355 | Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma | completed | Phase 3 | 712 | Radiation Therapy Oncology GroupNETWORK | 0 | Nov 12, 2019 | clinicaltrials |
| NCT04157478 | Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma | unknown | Phase 2 | 464 | People's Hospital of Guangxi Zhuang Autonomous RegionOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT03460782 | An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas | no longer available | — | — | Center Trials & TreatmentOTHER | 8 | Nov 8, 2019 | clinicaltrials |
| NCT00035373 | Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols | terminated | — | 767 | National Cancer Institute (NCI)NIH | 1 | Nov 7, 2019 | clinicaltrials |
| NCT01756352 | FET-PET for Evaluation of Response of Recurrent GBM to Avastin | completed | Phase 2 | 13 | Marcelo F. Di Carli, MD, FACCOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT01989884 | An Efficacy Study Of Ortataxel In Recurrent Glioblastoma(Ortataxel) | completed | Phase 2 | 45 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Oct 23, 2019 | clinicaltrials |
| NCT00892177 | Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme | completed | Phase 2 | 144 | Alliance for Clinical Trials in OncologyOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT02374255 | Improving Goals of Care Discussion in Advanced Cancer Patients | completed | N/A | 265 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT02017249 | Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme(ArginineGBM) | completed | Phase 1 | 1 | Inova Health Care ServicesOTHER | 1 | Sep 16, 2019 | clinicaltrials |
| NCT00295815 | Enzastaurin Versus Lomustine in Glioblastoma | completed | Phase 3 | 397 | Eli Lilly and CompanyINDUSTRY | 14 | Sep 12, 2019 | clinicaltrials |
| NCT01454596 | CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII | completed | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2019 | clinicaltrials |
| NCT02364206 | Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma(GLYRad) | completed | Phase 1 / Phase 2 | 18 | Centre Jean PerrinOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT03480867 | Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)(PARADIGMA) | withdrawn | Phase 1 | 0 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT01514201 | Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2019 | clinicaltrials |
| NCT03246113 | Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma | terminated | Phase 1 | 1 | New York State Psychiatric InstituteOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT03997136 | Prognostic Impact of Surgical Resection Extent for Supratentorial High Grade Gliomas. | unknown | — | 28 | Assiut UniversityOTHER | 0 | Aug 7, 2019 | clinicaltrials |
| NCT00423735 | Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 3 | Jul 24, 2019 | clinicaltrials |
| NCT00884741 | Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 3 | 637 | National Cancer Institute (NCI)NIH | 3 | Jul 24, 2019 | clinicaltrials |
| NCT02202993 | TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM | completed | Phase 1 | 18 | Cavion, Inc.INDUSTRY | 1 | Jul 24, 2019 | clinicaltrials |
| NCT03123952 | Expanded Access to ABT-414 | no longer available | — | — | AbbVieINDUSTRY | 0 | Jul 15, 2019 | clinicaltrials |
| NCT02520635 | Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients | unknown | — | 180 | Beijing Tiantan HospitalOTHER | 1 | Jul 11, 2019 | clinicaltrials |
| NCT03392545 | Combination of Immunization and Radiotherapy for Malignant Gliomas (InSituVac1)(InSituVac1) | unknown | Phase 1 | 30 | Beijing Tiantan HospitalOTHER | 1 | Jul 11, 2019 | clinicaltrials |
| NCT04004975 | Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib | unknown | Phase 1 / Phase 2 | 50 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jul 2, 2019 | clinicaltrials |
| NCT04002804 | Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Recurrence Of Glioblastoma Multiforme(Dendr2) | terminated | Phase 1 | 26 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 0 | Jul 1, 2019 | clinicaltrials |
| NCT02337426 | Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 | 12 | Virginia Commonwealth UniversityOTHER | 1 | Jun 28, 2019 | clinicaltrials |
| NCT03626896 | Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients | completed | N/A | 6 | NaviFUS CorporationINDUSTRY | 1 | Jun 21, 2019 | clinicaltrials |
| NCT01478854 | Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide | completed | N/A | 33 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 13, 2019 | clinicaltrials |
| NCT00262730 | Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM | completed | Phase 2 | 97 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 12, 2019 | clinicaltrials |
| NCT01564914 | A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma(105GM201) | completed | Phase 2 | 22 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Jun 12, 2019 | clinicaltrials |
| NCT00645385 | Examination of Changes on Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) in Patients Who Receive Gliadel Wafers During Initial Surgery for Glioblastoma Multiforme. Response or Failure to Gliadel Wafers for Subjects With Glioblastoma Multiforme.(Gliadel-MRS) | withdrawn | — | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT02120287 | Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme | completed | Phase 2 | 16 | Ajay NiranjanOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT00576537 | Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors | completed | Phase 2 | 50 | Cedars-Sinai Medical CenterOTHER | 1 | May 3, 2019 | clinicaltrials |
| NCT01109095 | CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM(HERT-GBM) | completed | Phase 1 | 16 | Baylor College of MedicineOTHER | 1 | Apr 25, 2019 | clinicaltrials |
| NCT03916757 | V-Boost Immunotherapy in Glioblastoma Multiforme Brain Cancer(GBM) | unknown | Phase 2 | 20 | Immunitor LLCINDUSTRY | 1 | Apr 17, 2019 | clinicaltrials |
| NCT00093964 | Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor) | completed | Phase 2 | 81 | EMD SeronoINDUSTRY | 1 | Apr 16, 2019 | clinicaltrials |
| NCT00961090 | Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery | completed | Phase 2 | 72 | Matthew R QuigleyOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT01209442 | Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme | completed | Phase 2 | 30 | University of Colorado, DenverOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT00902577 | MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Apr 8, 2019 | clinicaltrials |
| NCT00509821 | Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma | completed | Phase 2 | 60 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 5, 2019 | clinicaltrials |
| NCT02395692 | Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma | terminated | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2019 | clinicaltrials |
| NCT03075514 | Ketogenic Diets as an Adjuvant Therapy in Glioblastoma(KEATING) | completed | N/A | 12 | University of LiverpoolOTHER | 1 | Apr 4, 2019 | clinicaltrials |
| NCT03403803 | Prognosis and Therapeutic Biomarkers for Glioblastoma Patients | terminated | — | 10 | Baylor Research InstituteOTHER | 1 | Mar 27, 2019 | clinicaltrials |
| NCT02410577 | 89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme | completed | N/A | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 19, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Dec 2, 2019source: clinicaltrials